Academy offers four translating evidence into practice sessions

dv1051025The Academy is presenting a series of much-anticipated translating evidence into practice sessions throughout the Annual Meeting in San Francisco.

“Translating Evidence into Practice: Acne Guidelines” (W006) will be presented from 1 to 3 p.m. Friday, March 20, with Bethanie J. Schlosser, MD, directing. Scheduled speakers and topics:

  • Dr. Schlosser: introduction and pre-session survey
  • Rachel Victoria Sabbag Reynolds, MD: overview and recent advances in pathogenesis of acne
  • Jonette Elizabeth Keri, MD, PhD: use of antibiotic therapy for acne
  • Megha M. Tollefson, MD: use of isotretinoin for acne
  • Julie Claire Harper, MD: use of hormonal therapy for acne
  • Diane M. Thiboutot, MD: role of diet in acne

There will also be panel discussion and post-session discussion of the survey, including all faculty members.

“Translating Evidence into Practice: Psoriasis Guidelines” (C010) will be presented from 9 a.m. to noon Saturday, March 21, by Alan Menter, MD, and Craig Elmets, MD.

The session will help physicians expand their knowledge base and improve clinical confidence and effectiveness in treating patients with psoriasis and psoriatic arthritis. The session will consist of six presentations with time available after each talk for interaction with the attendees. It will be structured in a question-and-answer format where case studies are discussed.

“Translating Evidence into Practice: Atopic Dermatitis Guidelines” (W020) will be led by Jon M. Hanifin, MD, from 1 to 3 p.m. Sunday, March 22.

This workshop will review the salient aspects of the recently completed AAD Guidelines on Atopic Dermatitis, focusing on adult and pediatric populations, comparing dermatology guidelines with those from the allergy community, and then contrasting the AAD Guidelines with Asian and European approaches.

Speakers scheduled are Kelly M. Cordoro, MD; Norito Katoh, MD, PhD; and Peter A. Lio, MD, FAAD.

“Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines” (W024) will be presented by Susan M. Swetter, MD, from 10 a.m. to noon Monday, March 23.

This session will provide an overview of current recommendations for evaluation and therapy of cutaneous (AJCC stages 0-II) melanoma, focusing on recently AAD and NCCN guidelines. Members of the AAD melanoma guidelines panel will address biopsy techniques, pathology assessment, baseline/surveillance studies, sentinel lymph node biopsy staging, and management of primary melanoma. Treatment of dermatologic side effects related to newer systemic therapies for advanced melanoma will be covered. The session also look at international melanoma guidelines and practices, focusing on those employed in Australia and New Zealand.

Speakers and topics:

  • Hensin Tsao, MD, PhD: Bx Techniques and Primary Surgery
  • Antoinette Foote Hood, MD: Pathology, AJCC Staging
  • Dr. Swetter: Workup/Follow-Up
  • Christopher K. Bichakjian, MD: Sentinel Lymph Node Biopsy
  • James M. Grichnik, MD, PhD: Alternative Therapies
  • Pascale Guitera, MD, PhD: Contrast with Australian Guidelines
  • Bernice Kwong, MD: Dermatologic Toxicites of Melanoma Drugs

Return to index